You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. The Sustainable Heartland Accelerator Regional Partnership (SHARP) Hub

    SBC: BBC ENTREPRENEURIAL TRAINING & CONSULTING LLC            Topic: 500

    Project Summary/Abstract Despite the investment of billions of dollars in biomedical research each year from NIH, barriers remain in effectively translating basic science discoveries from academia to commercial products that benefit patients. These barriers include a funding gap between basic research and commercial developments, a lack of knowledge by innovators on how to bring products to market ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Pre-clinical Development of a Broad Spectrum Antiviral Compound to Treat Human Pa

    SBC: NANOVIR, LLC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The proposal seeks support for the pre-clinical development of broad spectrum compounds for treatment of human papillomavirus (HPV). HPV, the most common sexually-transmitted virus, is the cause of cervical dysplasia and cervical cancer. It has also been implicated in several other hyperproliferative diseases, such as cancers of the mouth and anus, as well as t ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a ZIKA viral pseudoinfectious virus as ZIKA vaccine candidate (STTR Phase II)

    SBC: Tengen Biomedical Co            Topic: NIAID

    Development of Zika viral pseudoinfectious virus as zika vaccine candidate(Phase 2) Abstract Zika virus epidemics and the association of ZIKV infection with Guillain–Barré syndrome, and congenital disabilities, including microcephaly, led the World Health Organization to declare ZIKV a “Public Health Emergency of International Concern” in 2016. Since then, various ZIKV vaccine platforms hav ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. Fluorescein for Sentinel Lymph Node Detection

    SBC: VESTAN INC            Topic: NCI

    DESCRIPTION (provided by applicant): In this Phase II STTR project, Vestan Medical Imaging, Inc. will complete the development and clinical evaluation of its proprietary formulation of a fluorescent drug and new medical devices for Sentinel Lymph Node (SLN) biopsy for the surgical treatment of melanoma and breast cancer. Vestan will partner with the University of Utah Huntsman Cancer Institute (HC ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. An Efficacy Trial of a Digital Therapeutic for Suicide Prevention

    SBC: OUI THERAPEUTICS INC            Topic: 104

    ABSTRACT Suicide is one of the top ten causes of death in the US and suicide rates have increased steadily over the last twenty years. Currently, the most effective treatment options are cognitive behavioral therapies for suicide prevention (CBT-SP), which have been shown to reduce both suicide attempt (SA) risk and suicide ideation (SI). However, access to these treatments is limited because ther ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Pre-Clinical HPV16 Antiviral Compound Development

    SBC: NANOVIR, LLC.            Topic: N/A

    Location NANOVIR, LLC. 4717 CAMPUS DR, STE 1300 KALAMAZOO, MI 49008 United States 2R42AI062182-03A1 $2 942 780.00 2 008 Pre-Clinical HPV16 Antiviral Compound Development Department of Health and Human Services National Institutes of Health STTR N N N PHS2 ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  9. Lentiviral-MGMT gene transfer into hematopoietic stem cells

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Bio-Effects of Ultra-High MRI Gradient Slew Rates

    SBC: WEINBERG MEDICAL PHYSICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): This application represents a competing renewal request for a Phase II STTR project, in which we constructed an ultra-fast gradient system for magnetic resonance imaging. Operation of the novel system is based upon theprinciple that the nervous system is relatively insensitive to very short exposures to changing magnetic fields. As a result, we are showing in c ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government